Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Related Citations for PubMed (Select 24685353)

1.

Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.

Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papadopoulos MC.

Acta Neuropathol Commun. 2014 Mar 31;2:35. doi: 10.1186/2051-5960-2-35.

2.

Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.

Rostásy K, Mader S, Hennes EM, Schanda K, Gredler V, Guenther A, Blaschek A, Korenke C, Pritsch M, Pohl D, Maier O, Kuchukhidze G, Brunner-Krainz M, Berger T, Reindl M.

Mult Scler. 2013 Jul;19(8):1052-9. doi: 10.1177/1352458512470310. Epub 2012 Dec 20.

PMID:
23257621
3.

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.

Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M.

J Neuroinflammation. 2011 Dec 28;8:184. doi: 10.1186/1742-2094-8-184.

4.

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.

Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Küker W, Chandratre S, Vincent A, Palace J.

JAMA Neurol. 2014 Mar;71(3):276-83. doi: 10.1001/jamaneurol.2013.5857.

PMID:
24425068
5.

Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury.

Marignier R, Nicolle A, Watrin C, Touret M, Cavagna S, Varrin-Doyer M, Cavillon G, Rogemond V, Confavreux C, Honnorat J, Giraudon P.

Brain. 2010 Sep;133(9):2578-91. doi: 10.1093/brain/awq177. Epub 2010 Aug 5.

6.

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC.

Brain. 2010 Feb;133(Pt 2):349-61. doi: 10.1093/brain/awp309. Epub 2010 Jan 4.

7.

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.

Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A.

Neurology. 2012 Sep 18;79(12):1273-7. doi: 10.1212/WNL.0b013e31826aac4e. Epub 2012 Aug 22.

PMID:
22914827
8.

Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms.

Zhang H, Bennett JL, Verkman AS.

Ann Neurol. 2011 Dec;70(6):943-54. doi: 10.1002/ana.22551. Epub 2011 Nov 8.

9.

Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.

Ratelade J, Verkman AS.

Int J Biochem Cell Biol. 2012 Sep;44(9):1519-30. doi: 10.1016/j.biocel.2012.06.013. Epub 2012 Jun 17. Review.

10.

MOG-IgG in neuromyelitis optica.

Luppe S, Robertson NP.

J Neurol. 2014 Mar;261(3):640-2. doi: 10.1007/s00415-014-7277-z. No abstract available.

PMID:
24532204
11.

Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.

Ratelade J, Zhang H, Saadoun S, Bennett JL, Papadopoulos MC, Verkman AS.

Acta Neuropathol. 2012 Jun;123(6):861-72. doi: 10.1007/s00401-012-0986-4. Epub 2012 Apr 22.

12.

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.

Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, Lino AM, Misu T, Leite MI, Aoki M, Fujihara K.

Neurology. 2014 Feb 11;82(6):474-81. doi: 10.1212/WNL.0000000000000101. Epub 2014 Jan 10.

13.

Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.

Ratelade J, Asavapanumas N, Ritchie AM, Wemlinger S, Bennett JL, Verkman AS.

Acta Neuropathol. 2013 Nov;126(5):699-709. doi: 10.1007/s00401-013-1172-z. Epub 2013 Aug 31.

14.

Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.

Verkman AS, Phuan PW, Asavapanumas N, Tradtrantip L.

Brain Pathol. 2013 Nov;23(6):684-95. doi: 10.1111/bpa.12085. Review.

15.

Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury.

Asavapanumas N, Verkman AS.

Acta Neuropathol Commun. 2014 Apr 24;2:48. doi: 10.1186/2051-5960-2-48.

16.

Neuromyelitis Optica Immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporin-4 expression and water permeability of the astrocyte plasma membrane.

Melamud L, Fernández JM, Rivarola V, Di Giusto G, Ford P, Villa A, Capurro C.

J Neurosci Res. 2012 Jun;90(6):1240-8. doi: 10.1002/jnr.22822. Epub 2012 Feb 22.

PMID:
22354518
17.

Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2.

Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, Howe CL, Pittock SJ, Lennon VA.

J Exp Med. 2008 Oct 27;205(11):2473-81. doi: 10.1084/jem.20081241. Epub 2008 Oct 6.

18.

Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica.

Ratelade J, Verkman AS.

Mol Immunol. 2014 Nov;62(1):104-13. doi: 10.1016/j.molimm.2014.06.003. Epub 2014 Jun 28.

PMID:
24980869
19.

[Recent progress in multiple sclerosis research: astrocytopathy in demyelinating diseases].

Kira J.

Rinsho Shinkeigaku. 2010 Nov;50(11):788-93. Review. Japanese.

PMID:
21921443
20.

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.

Mao Z, Lu Z, Hu X.

Neurology. 2014 Sep 16;83(12):1122. doi: 10.1212/WNL.0000000000000830. No abstract available.

PMID:
25224530
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk